Read Summary

Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.
Medscape Medical News

Print Friendly, PDF & Email